Global Health Limited reported robust financial results for the quarter and year ended March 31, 2026. The company achieved a consolidated annual revenue of ₹44,102.66 million and a net profit of ₹5,540.68 million. Following this strong performance, the Board of Directors has recommended a final dividend of ₹0.50 per share. Additionally, the company announced strategic leadership changes, including the appointment of new senior executives to drive future marketing and legal growth.
Annual Financial Performance Highlights
Global Health Limited has delivered a strong financial performance for the fiscal year ended March 31, 2026. On a consolidated basis, the company reported an annual revenue of ₹44,102.66 million, reflecting significant growth compared to the previous year. The annual consolidated net profit reached ₹5,540.68 million, underscoring the company’s operational efficiency and market strength. For the final quarter, consolidated revenue stood at ₹11,590.47 million with a profit after tax of ₹1,416.53 million.
Dividend and Shareholder Value
Recognizing the company’s solid financial health and commitment to delivering shareholder value, the Board of Directors has recommended a final dividend of ₹0.50 per equity share (representing 25% of the face value of ₹2). This dividend payout is subject to approval by the shareholders at the upcoming Annual General Meeting (AGM) and will be disbursed within 30 days of the meeting.
Strategic Leadership Appointments
To support its long-term strategic objectives, the company has announced key leadership changes effective May 14, 2026. Mr. Kedar Ashok Apte has been appointed as the Chief Marketing & Growth Officer, bringing over 23 years of experience from major global brands. Additionally, Mr. Jagdeep Singh has joined as General Counsel, leveraging his 18 years of expertise in legal, compliance, and governance frameworks. These appointments reflect the company’s intent to strengthen its executive leadership team.
Expansion and Development Initiatives
Global Health Limited is actively expanding its clinical footprint. During the final quarter, the company finalized a definitive agreement to develop a 400-bed multi-specialty hospital in Varanasi, Uttar Pradesh. Furthermore, following the close of the financial year, the company signed a Business Transfer Agreement to acquire a 79-bedded advanced super-specialty hospital focused on oncology services in Indore, further solidifying its presence in high-growth healthcare markets.
Source: BSE
